Navigation Links
Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Date:4/28/2009

up to be extremely interesting in light of recent UK directives from the Department of Health concerning mandatory MRSA screening for all elective admissions and other developments in infection control across Europe," said Dr. David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "Additionally, we expect to showcase our Xpert(R) MTB/RIF test for Mycobacterium tuberculosis - a product that, in my opinion, is one of the most important diagnostic developments to have occurred in many years."

Xpert MTB/RIF not only detects the presence of TB organism directly from sputum in less than two hours, but also identifies whether the strain is resistant to rifampicin, a commonly used first-line drug for treatment of the disease. Many studies have shown that rifampicin resistance is a reliable surrogate marker of strains that are multidrug-resistant TB (MDR-TB), and the frequency of MDR-TB is increasing in the EU. The test is expected to enable clinicians to dramatically improve the way they initially manage tuberculosis by helping them to make the right therapeutic decision on the first day of the initial patient encounter.

Cepheid currently offers European clinicians a broad menu of on-demand molecular diagnostic tests designed to enhance patient management. The full menu of CE IVD tests expected to be available for demonstration at booth #611 include:

  • Xpert(R) MTB/RIF
    • Diagnostic test for the simultaneous detection of Mycobacterium tuberculosis and resistance to rifampicin
  • Xpert(R) C. difficile
    • Diagnostic test for Clostridium difficile infection
  • Xpert(R) vanA/vanB
    • Detection of vanA and vanB, the genes most associated with hospital-acquired vancomycin-resistant enterococci (VRE)
    '/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid Reports 2009 First Quarter Results
2. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
3. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Cepheid to Webcast Upcoming Financial Presentations
6. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
7. Cepheid Reports Third Quarter Revenue of $44.9 Million
8. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
9. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
10. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
11. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... OSAKA, Japan, August 16 /PRNewswire-FirstCall/,-- Santhera Pharmaceuticals ... with a focus on neuromuscular diseases, and ... that the European Medicines Agency (EMEA) has ... (MAA) for Santhera,s lead compound,SNT-MC17 (INN: idebenone, ...
... Aug. 16 Cancer patients fraught with,flare-ups of ... assistance,in the form of a new easy-to-use oral ... quickly deliver pain medication. Cancer patients frequently ... cancer pain is characterized as continuous pain,present for ...
... 16 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... 2007 the,Nasdaq Listings Qualifications Department informed the Company ... below $50 million for 10,consecutive days, which is ... Market according to Marketplace Rule 4450(b)(1)(A). Nasdaq,also informed ...
Cached Biology Technology:European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6Novel Technology Breaks Through Cancer Pain 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... As researchers continue to examine the role ... people understand the differences among various ingredients used ... Association (CRA). Interchanging two distinctly different ingredients, such ... creates factually incorrect conclusions and misleads ,consumers. ...
... 4, 2009 Ben-Gurion University of the Negev engineers ... large nuclear reactors, making it unsuitable for use in ... form of the basic synthetic element found in commercial ... used for peaceful purposes. , This technique could help ...
... and very large reductions in greenhouse gas emissions compared ... messages from a series of expert papers on "The ... a special issue of Biofuels, Bioproducts and Biorefining ... which includes a comparative analysis of more than a ...
Cached Biology News:Pure fructose frequently confused with high fructose corn syrup 2Ben-Gurion University engineers develop technique to help combat nuclear proliferation 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: